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ABSTRACT 
To explore the association between autism phenotype and FMR1 protein (FMRP), FMR1 mRNA and 
CGG repeat length in 31 male FMR1 premutation carriers aged 3.0 to 27.9 years old (mean 13.0 ± SD 
6.5) using the ADOS communication, social interactive and total scores. FMRP levels were 
determined using the sandwich  Enzyme-linked Immunosorbent Assay (ELISA) method, FMR1 
mRNA expression levels were measured by qRT-PCR, and CGG repeat size was determined using 
Southern blot and PCR analyses. There was no significant difference in FMRP, CGG repeat length, 
and FMR1 mRNA between fifteen subjects without (ASD / PDDNOS / autism and sixteen subjects 
with ASD / PDDNOS / autism. ADOS scores were not significantly associated with either FMRP or 
FMR1 mRNA, This preliminary evaluation found that autism phenotype is not associated with the 
level of expression of either FMR1 mRNA or FMRP. However, CGG was significantly negative 
associated with both ADOS communication score (p= 0.0173) and ADOS total score (p= 0.0358). 
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The expansion of the CGG repeat in the 
premutation range (55-200 CGG repeats) of the 
fragile X mental retardation 1 gene (FMR1) can 
lead to a range of clinical involvement, including 
psychological  problems 1,2; fragile X-associated 
primary ovarian insufficiency (FXPOI) 3,4; 
immune-mediated disorders 5,6; hypertension 7; 
fragile X-associated tremor/ataxia syndrome 
(FXTAS) 8–10 and neurodevelopmental disorders, 
such as autism spectrum disorders (ASD) and 
attention deficit hyperactivity disorder (ADHD) 
11,12. Some of behaviours associated with autism 
such as avoidance of eye gaze, hand flapping, 
repetitive behaviours, and speech perseverations 
have been reported in more than 60% of all 
individuals with fragile X syndrome (FXS) 13–15. 
A lack or deficiency of the FMR1 protein 
(FMRP) in individuals with the full mutation 
(>200 CGG repeats) leads to the clinical features 
of FXS16. However, FMRP may be also mildly 
deficient in some individuals with the 
premutation, particularly those with CGG repeats 
in the upper premutation range as well as the 
premutation CGG Knock-In (CGG KI) mouse 
model 17–20. In addition, elevated level of FMR1 
mRNA, which rises with increased CGG-repeat 
number, is the most consistent molecular 
abnormality observed in both human and mouse 
premutations 20–23. Elevated mRNA also leads to 
central nervous system (CNS) toxicity and 
neurological disease, such as FXTAS and 
psychopathology in older carriers 1,2,24. 
Although most individuals with the 
premutation are unaffected by intellectual 
disability, a subgroup of children experience ASD, 
ADHD, anxiety, seizures, and learning difficulties 
or intellectual disability 12,13,25–29. The prevalence 
of ASD in boys with the premutation whose 
parents sought  medical attention for their sons' 
behaviour problems in the clinic (probands)  is 
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high (73%); however, if the premutation is 
identified through cascade testing, brothers with 
the premutation (non-probands) are then found to 
have a lower prevalence of ASD (14%)11. A 
questionnaire study of more than a thousand 
families demonstrated a prevalence of autism or 
ASD of 13% in boys with the premutation and 1% 
in girls with the premutation 28.  
The cause of the developmental problems in 
some premutation children is likely related to 
mild deficits of FMRP 12,17  in addition to the toxic 
effect of elevated mRNA 30–32. A recent report by 
Chonchaiya et al. found that seizures were 
common in male probands with the premutation 
and were significantly associated with ASD and 
intellectual disability in these boys 29. A study 
demonstrated that 11.3% had seizures of 57 
premutation boys from a family survey 28. In the 
CGG KI mice, the CGG premutation animal 
model, neurons appear to die more easily in 
culture than in control neurons  33, and these 
neurons have an enhanced frequency of 
electrophysiological spikes 34; thus the 
premutation neurons appear to be more 
vulnerable to seizures or other environmental 
toxicity. There are case reports of carriers who 
have been exposed to environmental toxins, 
including chemotherapy 35 or industrial 
contaminants 36, and have suffered more severe 
neurological problems than typically seen in 
carriers.  
The prevalence of the fragile X premutation in 
the general population is estimated at one in 130 
to 259 females and one in 250 to 813 males 37,38. 
Because the premutation is relatively common, 
some of the problems in premutation carriers may 
be exacerbated by other factors, in addition to low 
FMRP or to the RNA toxicity of elevated mRNA. 
The association between autism and FMR1 
expression has been studied in the full mutation 
range such an association has not been reported 
in those with premutation. In this study, we 
utilized enzyme-linked immunosorbent assay 
(ELISA) to measure FMRP levels in blood 39 and 
assessed the association between FMRP, FMR1 
mRNA, and CGG repeats and three ASD scores: 
communication score, social interactive score, and 
total score.  
 
SUBJECTS AND METHODS 
Subjects 
Subjects participated in studies at the MIND 
Institute at the University of California, Davis, 
between 2006 and 2011. The subjects included 31 
male premutation carriers with mean age 13.0, 
SD 6.5 (3.0 to 27.9 years). Parents and 
participants older than 8 years signed consent 
approved by our institutional review board. 
Premutation status was confirmed in all 
participants, as described below. Subjects 
underwent a full medical evaluation, which 
involved a medical history and a physical / 
neurological examination by one of the authors 
(RJH), an expert in neurodevelopmental 
disorders. The medical history involves a detailed 
review of systems and questions regarding 
medical conditions, such as history of 
development, and medical problems, including 
seizures. We classified the subjects into probands 
and non-probands.  Probands were individuals 
who presented to the clinic because of their 
medical or developmental problems, while 
individuals who were identified by cascade testing 
named as non-probands. 
During the clinical evaluation, assessment of 
specific measures for ASD were completed by 
licensed psychologists. The diagnostic algorithm 
of the Autism Diagnostic Observation Schedule 
(ADOS) module 1,2,3 and 4  were used to examine 
the profile of autism.  40 From the ADOS 
examination, the subjects were diagnosed with 
ASD, PDDNOS or autism. The participants were 
then divided into two groups, group A with no 
ASD/ PDDNOS/autism or were in typical range 
and group B with ASD/PDDNOS/autism  
 
Molecular Measures 
FMRP was determined using the sandwich 
ELISA method published previously 39. FMR1 
mRNA expression levels, measured by qRT-PCR 
were as described 41. CGG repeat size was 
determined using Southern blot and PCR 
analyses, as previously described 37. 
 
Statistical Analysis 
Descriptive statistical analysis was based on 
Fisher exact test for categorical variable and 
student’s t test for continuous variables. To test 
association between ASD scores and molecular 
biomarkers (FMRP, FMR1 mRNA, CGG repeats), 
the analysis of covariance (ANCOVA) was used to 
with covariates group effect and FMRP or FMR1 
mRNA or CGG repeat. Differential association 
between ADOS variables depending on whether 
premutation carriers in group A or B were 
assessed with inclusion of interaction term with 
group; however, the all interaction terms were not 
statistically significant. All statistical analysis 
was conducted in SAS version 9.2.  
 
RESULTS 
Characteristics of study subjects 
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The initial cohort included 31 males who carried 
an FMR1 allele with CGG repeats number from 
55 and 186 (Mean 101, SD 40). Relative FMRP 
levels were measured from blood lymphocytes 
with levels ranging from 0.65 to 2.27 (Mean 1.57, 
SD 0.5), where a value of 1.0 is the mean FMRP 
value derived from controls with normal alleles. 
The analysis cohort included 31 subjects based on 
ADOS overall diagnosis: 8 (25.81%) subjects had 
PDDNOS; 7 (22.58%) subjects had autism; 1 
(3.23%) subject had ASD, and 15 (48.39%) subjects 
either did not have ASD/PDDNOS/autism. Among 
participants, three individuals (9.67%) 
experienced seizures and all of them had been 
diagnosed with ASD.   
Although FMRP levels were negatively 
correlated with CGG repeat length (p= 0.0465). 
FMRP levels in group A (N 15, Mean 1.53, SD 
0.52) were not significantly different (p= 0.7782) 
from values for the group B (N 16, Mean 1.59, SD 
0.59).  
Group A consisted of 9 (60%) subjects who were 
identified as probands and 6 (40%) as non-
probands.  Group B consisted of 11 (68.75%) 
subjects who were identified as probands and 5 
(31.25%) as non-probands. Among the probands in 
group A, 7 (64%) had ADHD, 3 (27%) individuals 
had learning difficulties, and 1 (9%) individual 
had intellectual disability. The prevalence of 
probands was not significantly different between 
the two groups (p=0.716). As expected, ADOS 
total, communication and social interactive scores 
differed between the two groups.  
 
Table 1 summarizes the study cohorts, including molecular variables, and ADOS outcome score
 
 A= No ASD/PDDNOS/autism B=ASD/PDDNOS/autism  
Variable N Mean SD N Mean SD P-value 
Age 15 13.50 7.70 16 12.56 5.70 0.7014 
CGG 15 
 
92 
(56-144)* 29 16 
109 
(55-186)* 48 0.233 
FMR1 mRNA 15 3.23 
 
1.29 16 3.21 1.84 0.9613 
FMRP 15 1.53 
 
0.52 16 1.59 0.59 0.7782 
Seizures        
Proband N %  N %   
 Yes 9 60.00  11 68.75  0.716 
No 6 40.00   5 31.25   
 
Association between ADOS communication, 
social interactive and total score with, FMR1 
expression and CGG expansion 
Table 2 summarizes the primary analyses 
to assess the association between ADOS 
scores with FMRP, FMR1 mRNA, and CGG 
among premutation groups (A= No 
ASD/PDDNOS/autism, B = 
ASD/PDDNOS/autism).  
 
There was no significant association between 
the three ADOS scores (communication, social 
interactive, total score) and either FMRP or 
FMR1 mRNA expression. CGG repeat length was 
significantly negatively associated with both 
ADOS communication score (p=0.0173) and 
ADOS total score (p=0.0358); see Table 2. For 
example, the total ADOS score declined by a 
modest 0.0394 unit for one CGG repeat increase 
(Table 2); thus, the model average ADOS total 
scores for an individual with 60, 90 or 130 CGG 
repeats are 5.1, 3.9, and 2.3, respectively (for 
premutation carriers without ASD). 
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Table 2 ADOS outcome score
 
Variable Parameter Estimate Standard Error P-value 
Model #1: ADOS score= Group* + FMRP 
ADOS Communication Score Intercept 0.1465 0.9106 0.8736 
  Group=B 2.5085 0.5920 0.0003 
  FMRP 0.5119 0.5358 0.3498 
ADOS Social Interactive Score Intercept 0.8415 1.3301 0.5335 
  Group=B 5.1733 0.8647 <.0001 
  FMRP 0.8998 0.7827 0.2627 
ADOS Total Score Intercept 1.0685 2.2496 0.6393 
  Group=B 6.8448 1.4227 <.0001 
  FMRP 1.8700 1.3108 0.1671 
Model #2: ADOS score= Group + FMR1 mRNA 
ADOS Communication Score Intercept 1.8301 0.8217 0.0365 
  Group=B 2.4577 0.5843 0.0004 
  FMR1 mRNA -0.2778 0.2111 0.2017 
ADOS Social Interactive Score Intercept 3.4861 1.2147 0.0089 
  Group=B 5.1296 0.8637 <.0001 
  FMR1 mRNA -0.3934 0.3120 0.2206 
ADOS Total Score Intercept 6.7056 1.9556 0.0023 
  Group=B 6.7464 1.4064 <.0001 
  FMR1 mRNA -0.8645 0.5170 0.108 
Model #3:  ADOS score= Group + CGG 
ADOS Communication Score Intercept 2.5550 0.7503 0.0025 
  Group=B 2.7371 0.5271 <.0001 
  CGG -0.0177 0.0069 0.0173 
ADOS Social Interactive Score Intercept 3.4725 1.2191 0.0093 
  Group=B 5.4328 0.8564 <.0001 
  CGG -0.0139 0.0112 0.2274 
ADOS Total Score Intercept 7.4645 1.8688 0.0006 
  Group=B 7.5273 1.3513 <.0001 
  CGG -0.0394 0.0177 0.0358 
*Group: A= No ASD, as reference; B = ASD/PDDNOS/Autism 
 
DISCUSSION 
ASD is common in the general population and 
occurs in as many as one in 88 individual.42 The 
etiologies of autism are numerous, including a 
number of known genetic disorders, though FXS 
is the most common single-gene disorder 
associated with autism.43 FMRP regulates the 
translation of many other proteins important for 
synaptic plasticity and whose genes are also 
associated with autism when mutated; when 
FMRP is absent, many of these gene products are 
dysregulated.  44 Fragile-X carriers especially boys 
who have CGG repeat number in premutation 
range can present with ASD although their 
etiology may be heterogeneous similar to 
idiopathic autism. 45 In this study, we investigated 
the role played by FMR1 molecular measures in 
leading to the ASD phenotype among premutation 
boys and found no correlation between autism 
phenotypes and both the level of FMRP and FMR1 
mRNA. However, we observed that CGG repeat 
number was significantly negatively associated 
with both ADOS communication score and ADOS 
total score; although the effect size was clinically 
modest. A variety of mRNA transcripts arise from 
a combination of alternative splicing, alternative 
transcriptional start sites selection and 
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differential usage of polyadenylation sites. In fact, 
these events generate the vast majority of 
diversity of gene expression and have been 
described for over 180 000 mouse transcripts. 
Besides alternative splicing, which can produce 
extraordinary protein diversity, regulation at the 
level of the 5′- and 3′-UTRs modulates mRNA 
processing, nuclear export, stability, subcellular 
localization and translational efficiency. Such 
processes are crucial for differential expression of 
a gene during development, tissue differentiation 
and under certain pathological conditions. Since 
our analysis cohort only had a small sample size 
of 31 subjects in total, the results need to be 
interpreted with caution. Larger studies are 
needed to provide more accurate estimate and to 
confirm the observed association reported here. 
Another important limitation of this preliminary 
evaluation is this association may be confounded 
by other factors that we may not have in the 
study, potentially genetic and environmental 
factors. Those with low CGG-repeat numbers are 
the most common group of premutation males and 
perhaps most likely to have autism for additional 
causes, confirming that the etiology of their 
autism may be multifactorial or similar to 
idiopathic autism. A publication demonstrates 
that approximately 20% of premutation carriers 
with ASD, ID or neurological problems can have a 
second genetic hit that may be additive to the 
premutation specifically a copy number variants 
(CNV) that may also be associated with autism or 
ID 46. 
The study population reported here included 
boys who were diagnosed with autism or ASD 
either before or after premutation status was 
established. Some presented as the proband of 
their family, and others were identified by cascade 
testing once a proband was diagnosed with FXS or 
premutation involvement. Because of the 
inclusion of probands with the premutation, our 
study is biased towards clinical involvement, 
particularly ASD in this group of patients. 
However, this is an optimal population of carriers 
to see if the levels of FMRP or mRNA are related 
to this type of clinical involvement. We observed a 
significant negative correlation between FMRP 
and CGG repeats. However, FMRP was not 
significantly associated with ADOS 
measurements (communication score, social 
interactive score, and total score). The large range 
of FMRP values in these premutation boys is 
similar to what has been reported in individuals 
with normal CGG repeats 39. Lowered FMRP 
levels have been seen in the blood and brain tissue 
of some premutation patients with developmental 
problems 12,17, and in both blood and brain of 
premutation mice18. Brain levels of FMRP may be 
significantly lower than blood levels in 
premutation carriers, particularly in areas of the 
brain important for social deficits such as the 
amygdala and insula. Therefore, low levels of 
FMRP may be present in the brain even when 
FMRP is not low in blood 47.  Fatemi et al have 
demonstrated low levels of FMRP in the brain in 
individuals with idiopathic autism without an 
FMR1 mutation, and in those with 
neuropsychiatric disorders such as 
schizophrenia48. Both age of onset and IQ 
correlates with level of FMRP in the blood of those 
with schizophrenia who do not have an FMR1 
mutation 48. Therefore, FMRP may be important 
for the clinical phenotype in a number of 
neuropsychiatric disorders.  
Premutation neurons lose viability more rapidly 
than control neurons in cell culture 33, and display 
an increase in spike-wave discharges 34 compared 
to controls. Therefore, environmental factors, 
such as infections or toxins, associated with 
autism would be more likely to cause deleterious 
effects in premutation neurons. There is also 
evidence of mitochondrial dysfunction in 
premutation carriers 49, which has been seen in 
fibroblasts and brain tissues from premutation 
carriers with and without FXTAS 34. 
Mitochondrial problems are also commonly seen 
in idiopathic autism 50. Mitochondrial 
abnormalities could possibly be related to the 
autism or ASD phenotype linked to RNA toxicity, 
even without lowered FMRP levels. A variety of 
environmental factors may elevate FMRP. Jeon et 
al. have reported that HeLa cells exposed to cell-
death inducer etoposide up-regulated FMRP 
levels.34 This effect was synchronized with 
phosphorylation of Akt, a known cell-survival-
related signaling molecule. Induction of FMRP 
apparently plays a protective role against the 
stressed status of cells and, with reduced FMRP, 
cell survival is compromised. The premutation is 
associated with higher rates of seizures in both 
the current premutation group and I n reports 
in the literature28. Chonchaiya et al. have shown 
that the presence of seizures is closely associated 
with the diagnosis of autism or ASD in 
premutation boys 29. On a cellular level, 
premutation neurons demonstrate enhanced 
spikes in culture, so it appears that RNA toxicity 
can predispose to seizures in premutation carriers 
34. Seizures in turn can lead to neurochemical 
changes in the CNS that can further exacerbate 
developmental problems 51 and seizures can pull 
FMRP away from the dendritic spines and into 
the cell body thereby depleting the dendrites of 
the regulatory effects of FMRP 52.  
We do not yet know why some individuals with 
the premutation have developmental problems or 
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ASD and others do not. The reasons are not 
simple, and they not seem to be related to FMRP 
levels or FMR1 mRNA levels in blood. There are 
likely additive and multifactorial effects that 
involve both background genetic and 
environmental effects. Further studies of 
neurotoxicants are warranted, and more detailed 
genomic studies are needed to better understand 
the neurodevelopmental effects of the 
premutation. 
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